Broadview Ventures Inc’s Post

RPT: Battles of the Alphas Breakthrough Therapy Designation is based on the results from phase 1 and the ongoing phase 2 clinical trials that assessed the safety and efficacy of AlphaMedixTM. In the phase 1 study, treatment was well-tolerated, with a response rate (ORR according to RECIST 1.1) of 62.5% for the GEP-NET patients who had never received PRRT with LutatheraTM, which is based on the beta-particle emitter Lutetium-177. In the phase 2 trial, the target response rate has already been achieved ahead of top-line data, expected in mid-2024.

Our CSO Martin Gosling was recently interviewed by Labiotech for an article discussing how new treatments for #cysticfibrosis (CF) are boosting life expectancy. Just three decades ago, the average life expectancy of people with CF was around 30 years of age. This has now improved to 50, with some patients living into their 80s. Recent advancements in CF research have played a key role in contributing to this. One section of the article discusses how Enterprise Therapeutic’s EDT001 has the potential to meet the needs of people with CF. In preclinical studies, ETD001 boosted the clearance of mucus for longer than 12 hours after a single dose, and Phase 1 studies showed a pharmacokinetic profile consistent with long lung retention. Phase 2 trials are due to begin this month. ETD001 has the potential to treat people with cystic fibrosis not currently eligible or receiving benefit from CFTR modulators, and further improve lung function when administered in combination with CFTR modulators. Read more about new treatments for people with #CF here: https://rb.gy/1jdi5x

We're excited to share details about our Phase 2 NEULARK trial of NEU-411, a brain-penetrant, potent and selective inhibitor of #LRRK2, in people living with early #Parkinsons disease (PD). The NEULARK trial represents a significant #precisionmedicine advancement in how we can effectively identify and measure therapeutic impact in LRRK2-driven PD, estimated to affect up to 30% of people living with the disease. Listen in as Chief Medical Officer Sam Jackson, EVP of Drug Discovery Steve Wood, and Executive Director of Clinical and Digital Development Fatta B. Nahab MD, FAAN, FANA, discuss the importance of NEU-411 and how this innovative trial in PD differentiates itself. Our LRRK2 program is a key driver of innovation within our neuroimmunology pipeline, and we are on track to initiate this trial early in 2025. Read more here: https://lnkd.in/eShmssCC

Sharing an in-depth look at the “radiopharma” competitive landscape, courtesy of OPCO. Dive into the latest insights on this potentially impactful modality that is poised to change the standard of care in oncology! #biotech #healthcare #medicine #radiopharma #oncology #cancer

"We've demonstrated the drug is antifibrotic. We know that it works, and that's a considerable step forward." – Gary Phillips, CEO In a recent update, our CEO Gary Phillips shared promising insights from our earlier study in myelofibrosis patients who had failed on JAK inhibitors. In these challenging cases, almost half of the patients experienced a reduction in bone marrow fibrosis, with many showing stable or improved blood counts and symptom relief. As we move forward with patients earlier in their treatment journey, we’re extending our current study to 12 months, aiming to demonstrate even greater clinical benefits. With a solid safety profile and encouraging signs of efficacy. #Syntara #SNT #Myelofibrosis #SNT5505 #ClinicalTrials #Biotech #Innovation #BloodCancer

🎉 Congratulations to Dignify Therapeutics for securing an impressive $389,852 grant from the U.S. Department of Health and Human Services (HHS) , awarded by the The National Institutes of Health and the NIH National Institute on Aging! This #SBIR award is set to revolutionize treatments for urinary incontinence and overactive bladder symptoms in the elderly. The project aims to develop new drug formulations that provide long-term relief for patients who are unresponsive to current therapies. By targeting nociceptors in the bladder, these drugs promise to maximize efficacy while minimizing side effects. 🔬 This groundbreaking research will span 1.67 years, starting on September 5, 2024, and concluding on May 31, 2026. The project will involve rigorous in vivo testing and aims to pave the way for future clinical studies. Kudos to Dignify Therapeutics for their innovative approach to improving elderly care! #STTR #HealthcareInnovation #ElderlyCare

NervGen’s CMO, Daniel Mikol MD, PhD, spoke with Greg Johnson of Radio Health Journal about NVG-291, NervGen’s lead drug candidate. NVG-291, which is currently being evaluated in a Phase 1b/2a clinical trial in spinal cord injury, has been shown to promote nervous system repair and improve functional recovery in preclinical animal models of nervous system damage. Listen to the interview here: https://lnkd.in/eRqtFKhd Visit www.connectscistudy.com to learn more about NervGen’s clinical trial for individuals living with spinal cord injury. #SCI #SpinalCordInjury 

Join us next Wednesday, May 22nd, 2024, for our webinar 'Current Gold Standards for MSI Testing and the Clinical Relevance of the MSI-H Biomarker'. 🧬 In this webinar, our expert Dr. Annette Burkhouse will provide an overview of current gold standards for microsatellite instability (MSI) testing and discuss the role of MSI testing in Lynch syndrome screening and the diagnosis and treatment of mismatch repair-deficient tumors. Learn about: ✔️ Different techniques to measure MSI and how they compare to current gold-standard methods ✔️ The clinical relevance of the MSI biomarker for Lynch syndrome screening and immunotherapy treatment ✔️ Current clinical practice guidelines for MSI testing Register now ➡️ https://bit.ly/3K0hWa2 #MicroSatelliteInstability #MSI #LynchSyndrome #MMRdeficiency #immunooncology #immunotherapy #webinar #lifesciences #biotech

📣 Join us for our upcoming webinar: Unlocking the full potential of immunopeptidomics with the timsTOF Ultra 📅 October 29, 2024 11:00 am - 12:00 pm EDT, 4:00 - 5:00 pm CET Why to join this webinar: The timsTOF Ultra can lead to high quality immunopeptidomes from limited sample Extensive HLA databases can significantly speed up the T-Cell-Receptor therapy development process The time is ripe to bring immunopeptidomics into clinical routine https://lnkd.in/efUZwFye

🧪 #FIPO: launch of the 3rd cohort in the clinical trial The scientific council has given the green light for the third dose in the ascending phase of our FIPO clinical trial. This Phase I/II trial tests the safety and efficacy of XON7 in patients with solid tumors. Key updates: ✅ Safety validated: after cohorts at 1.5 mg/kg and 3 mg/kg, the safety of XON7 has been confirmed. 👩⚕️ New cohort: 3 patients with solid tumors are now being treated at 6 mg/kg across our Foch, Lyon, and Toulouse centers. 📈 Ascending phase: we are progressively increasing doses to ensure safety and assess the benefit/risk ratio of XON7. 💫 Hope for patients: XON7 represents a new hope for patients who have not responded to current treatments. 🔍 More information in our carousel. #ClinicalTrial #XON7 #Biotech #Innovation #PatientCare